Countries covered: Global
This report analyzes the worldwide markets for Respiratory Drugs in US$ Million. The major product segments analyzed are Asthma, Allergic Rhinitis, and COPD (Chronic Obstructive Pulmonary Disease). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2010. The report profiles 69 companies including many key and niche players worldwide such as Accentia Biopharmaceuticals, Inc., Aerogen, Inc., Aerovance, Inc., airPharma, AstraZeneca, Aventis Pharma Limited, Bespak, Boehringer Ingelheim Pharmaceuticals, Inc., Cadila Pharmaceuticals, Dr. Reddy's Laboratories, EvoGenix, GlaxoSmithKline, GlaxoSmithKline Pharmaceuticals Ltd., Inyx, Inc., The Merck Generics Group, Novartis AG, Pfizer, Inc., Ranbaxy Laboratories Limited, Respironics, Inc., Sandoz International GmbH, and Schering-Plough Corp. Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location. Adobe Acrobat Reader 7.0 is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Titles available via "online download" are not affected by this and are still delivered to your personal library immediately.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
|
- I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
- II. EXECUTIVE SUMMARY
- 1. Market Overview
- Respiratory Diseases - Common and Serious
- Rhinoviruses - Root Cause of Major Respiratory Diseases
- Leading Asthmatic Drugs and their Patent Expiries
- Antihistamine or Allergic Rhinitis Market
- Leading Anti-Allergy Drugs and Patent Expiry Years
- Current and Future Analysis
- Regional Perspective
- Product Segment Perspective
- 2. Common Respiratory Diseases - Overview
- Influenza
- Asthma
- Factors Promoting Asthma
- Treatment
- Respiratory Distress Syndrome (RDS)
- Symptoms
- Complications Related to RDS
- Analysis of RDS
- Alternative Methods for the Treatment of RDS
- Preventive Measures
- Chronic Obstructive Pulmonary Disease
- Characteristics and Symptoms of COPD
- Risks Associated with COPD
- Bronchitis
- Respiratory Syncytial Virus (RSV)
- 3. Treatment of Respiratory Diseases - An Overview
- Respiratory Therapy with Information Technology
- Antiviral Drugs for Controlling Influenza and RSV Infections
- Pulmonary Drug Delivery
- Why are Lungs Considered a Good Alternative?
- COPD - Taking a Toll on Human Lives
- Upper Respiratory Tract Infections (URIs)
- Respiratory Failure Management
- CPAP: Non-Invasive Respiration
- Face Masks: Carriers of Oxygen Therapy
- Endotracheal Intubation and Ventilatory Support
- Endotracheal Intubation Turns Perilous
- Ventilator Strategy
- Methods of Ventilation
- Weaning from the Ventilator
- Respiratory Support: A Broader Perspective
- Humidification
- Posture
- Physiotherapy
- Pharmacological Adjuncts
- Sedation
- New Drugs, Treatments Ease Life of Patients with Respiratory Problems
- Progesterone
- Partial Liquid Ventilation
- Heliox
- High-level PREP
- Respiratory Failure
- Types of Respiratory Failure
- Factors Leading to Respiratory Failure
- Blockage of air passage
- Drug abuse or alcohol addiction
- Obesity
- Muscle weakness
- Lung disorders and diseases
- Abnormalities in Chest Walls
- Cellular Disorders
- Treatment for Respiratory Failure
- Role of Health Care Teams
- Long-Term Consequences of Respiratory Failures
- Preventive Measures
- Measures to Prevent the Recurrence of Respiratory Diseases
- Telithromycin: Treatment for Respiratory Disorders
- Consequences of Telithromycin
- 4. Recent Industry Activity
- Arcadia Resources, Inc Acquires Remedy Therapeutics, L.L.C
- Sirna Forms Alliance with GlaxoSmithKline
- Pharmaxis Ltd and Nigaard Pharma Enters into Distribution Agreement
- Teva Regains Leadership Position through Ivax Acquisition
- AstraZeneca Submits Symbicort for US FDA Approval
- Ranbaxy Laboratories Receives FDA Approval
- Innovata Inks Development Agreement for Duohaler
- Novartis Obtains License from Arrow Therapeutics for A60444 Molecule Inhibitor
- Arakis Ltd and Vectura Group plc Initiate Phase IIb Clinical Trial of NVA237
- Schering-Plough Receives FDA Approval for Asmanex
- Isis Pharmaceuticals Develops ISIS 369645
- Inyx Acquires Celltech Manufacturing Services from UCB
- Ashton Pharmaceuticals Partners with Innovata and Merck
- King Pharmaceuticals Collaborates with Inyx
- Inyx Pharma Ltd. Bags a Contract from Generics
- Alnylam Pharmaceuticals Initiates Phase I Trials on ALN-RSV01
- MAP and Elan Extend their Agreement for Developing Advanced Version of Asthma Drug
- Accentia Enters into Licensing Agreement with Collegium
- Novartis Inks Agreement with Arakis and Vectura
- Pfizer and Rigel Sign Collaborative Agreement
- NicOx Enters into Developing and Licensing Agreement with Topigen
- Merck to Strike a Licensing Deal with Innovata for Developing Respiratory Medicines
- Lannett Receives Approval from FDA for the Distribution of Terbutaline Sulfate Tablets
- GlaxoSmithKline Licenses Inhaled Respiratory Therapy from Theravance
- Novartis’ Sandoz Completes Acquisition of Hexal AG
- Sandoz Acquires Eon Labs
- SkyePharma, PLC Enters into License Agreement with GlaxoSmithKline
- Kos Pharmaceuticals Signs Agreement with Aventis Pharmaceuticals
- US FDA Approves New Antibiotic, Ketek
- Zambon Terminates Single-Agent Inhaler Project
- Boehringer Ingelheim Pharmaceuticals Obtains FDA Approval for Atrovent HFA
- Ranbaxy Receives FDA Approval for Loratadine and Pseudoephedrine Sulfate Tablets
- Lincoln Pharmaceuticals Limited Introduces Gatilink, an Antibiotic
- GlaxoSmithKline Forms Alliance with Theravance
- Etiologics Acquires Bayer’s Pre-clinical Respiratory Research Group
- IVAX Pharmaceutical Signs Pan-European Agreement with 3M
- GlaxoSmithKline Inks Agreement with Theravance
- Cadila Pharmaceuticals Ltd Launches Montelast for Asthma
- Alpharma Unveils Generic Loratadine Syrup
- Dr. Reddy’s Laboratories Launches Brancho-Vaxom
- 5. Focus on Select Players
- Accentia Biopharmaceuticals, Inc. (US)
- Aerogen, Inc. (US)
- Aerovance, Inc (US)
- airPharma (US)
- AstraZeneca (UK)
- Aventis Pharma Limited (India)
- Bespak (UK)
- Boehringer Ingelheim Pharmaceuticals, Inc (Germany)
- Cadila Pharmaceuticals (India)
- Dr. Reddy's Laboratories (India)
- EvoGenix (Australia)
- GlaxoSmithKline (US)
- GlaxoSmithKline Pharmaceuticals Ltd. (India)
- Inyx, Inc. (US)
- The Merck Generics Group (Germany)
- Novartis AG (Switzerland)
- Pfizer, Inc. (US)
- Ranbaxy Laboratories Limited (India)
- Respironics, Inc (US)
- Sandoz International GmbH (Germany)
- Schering-Plough Corp (US)
- 6. Global Market Perspective
- Table 1: Recent Past, Current and Future Analysis for Respiratory Drugs by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 2: World 10-Year Perspective for Respiratory Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- Table 3: World Recent Past, Current and Future Analysis for Asthma Drugs by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 4: World 10-Year Perspective for Asthma Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- Table 5: World Recent Past, Current and Future Analysis for Allergic Rhinitis Drugs by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 6: World 10-Year Perspective for Allergic Rhinitis Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- Table 7: World Recent Past, Current and Future Analysis for Chronic Obstructive Pulmonary Disease (COPD) Drugs by Geographic Region - US, Canada, Japan, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 8: World 10-Year Perspective for Chronic Obstructive Pulmonary Disease (COPD) Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe and Rest of World Markets for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- III. MARKET
- 1. The United States
- A.Market Analysis
- Current & Future Analysis
- Market Scenario
- Asthma
- COPD
- Leading Respiratory Drug Brands
- Strategic Corporate Developments
- Focus on Select Players
- B.Market Analytics
- Table 9: US Recent Past, Current and Future Analysis for Respiratory Drugs by Product Segment - Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 10: US 10-Year Perspective for Respiratory Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
2. Canada
- Market Analysis
- Table 11: Canadian Recent Past, Current and Future Analysis for Respiratory Drugs by Product Segment - Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 12: Canadian 10-Year Perspective for Respiratory Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
3. Japan
- Market Analysis
- Table 13: Japanese Recent Past, Current and Future Analysis for Respiratory Drugs by Product Segment - Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 14: Japanese 10-Year Perspective for Respiratory Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
4. Europe
- A.Market Analysis
- Current & Future Analysis
- Strategic Corporate Developments
- Focus on Select Players
- B.Market Analytics
- Table 15: European Recent Past, Current and Future Analysis for Respiratory Drugs by Product Segment - Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 16: European 10-Year Perspective for Respiratory Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
5. Rest of World
- A.Market Analysis
- Current & Future Analysis
- Strategic Corporate Developments
- Focus on Select Players
- B.Market Analytics
- Table 17: Rest of World Recent Past, Current and Future Analysis for Respiratory Drugs by Product Segment - Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs Independently Analyzed by Annual Sales in US$ Million for the Years 2000 through 2010 (includes corresponding Graph/Chart)
- Table 18: Rest of World 10-Year Perspective for Respiratory Drugs by Product Segment - Percentage Breakdown of Dollar Sales for Asthma Drugs, Allergic Rhinitis Drugs and Chronic Obstructive Pulmonary Disease (COPD) Drugs for the Years 2000, 2006 and 2010 (includes corresponding Graph/Chart)
- IV. COMPETITION
- 1. 3M Company (USA)
- Table 19: First Quarter Sales Analysis: 2005-2006 (In US$ million)
- Table 20: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ million)
- Table 21: Annual Sales Analysis: 2004-2005 (In US$ million)
- Table 22: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
- Table 23: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
- Table 24: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
- 2. Accentia Biopharmaceuticals (USA)
- Table 25: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
- Table 26: Half Yearly Sales Analysis by Business Segment: 2005-2006 (H1) (In US$ million)
- Table 27: Half Yearly Sales Analysis by Quarter: 2005- 2006 (H1) (In US$ million)
- Table 28: Annual Sales Analysis: 2004-2005 (In US$ million)
- Table 29: Annual Sales Analysis by Business Segment: 2004-2005 (In US$ million)
- Table 30: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
- 3. Activaero GmbH (Germany)
- 4. Actavis (Iceland)
- 5. Acusphere, Inc. (USA)
- Table 31: First Quarter Sales Analysis: 2005-2006 (In US$ thousands)
- Table 32: Annual Sales Analysis: 2004-2005 (In US$ thousands)
- 6. Aerovance, Inc. (USA)
- 7. Airpharma LLC (USA)
- 8. Alkermes, Inc. (USA)
- Table 33: Annual Sales Analysis: 2004-2006 (In US$ million)
- 9. Alnylam Pharmaceuticals, Inc. (USA)
- Table 34: First Quarter Sales Analysis: 2005-2006 (In US$ million)
- Table 35: Annual Sales Analysis: 2004-2005 (In US$ million)
- Table 36: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
- 10. Altana AG (Germany)
- Table 37: First Quarter Sales Analysis: 2005-2006 (In € million)
- Table 38: Annual Sales Analysis: 2004-2005 (In € million)
- Table 39: Annual Sales Analysis by Segment: 2004-2005 (In € million)
- Altana Pharma Pvt., Ltd. (India)
- 11. Argenta Discovery Ltd. (UK)
- 12. Arrow Therapeutics (UK)
- 13. Ashton Pharmaceuticals Limited (UK)
- 14. Astrazeneca PLC (UK)
- Table 40: First Quarter Sales Analysis: 2005-2006 (In US$ million)
- Table 41: First Quarter Sales Analysis by Geographic Region: 2005-2006 (In US$ million)
- Table 42: Annual Sales Analysis: 2003-2005 (In US$ million)
- Table 43: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
- 15. AtheroGenics, Inc. (USA)
- 16. Aurobindo Pharma Ltd. (India)
- Table 44: Annual Sales Analysis: 2004-2005 (In INR million)
- 17. Bespak PLC (UK)
- Table 45: Annual Sales Analysis: 2004-2005 (In £ million)
- Table 46: Annual Sales Analysis by Segment: 2004-2005 (In £ million)
- Table 47: Annual Sales Analysis by Geographic Region: 2004-2005 (In £ million)
- 18. Boehringer Ingelheim GmbH (Germany)
- Boehringer Ingelheim Pharmaceuticals, Inc. (Germany)
- Boehringer Ingelheim Ltd. (Germany)
- Nippon Boehringer Ingelheim Co., Ltd. (Japan)
- 19. Breath Limited (USA)
- 20. Cadila Pharmaceuticals Ltd. (India)
- 21. Cardinal Health, Inc. (USA)
- Table 48: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, March) (In US$ billion)
- Table 49: Nine Months Sales Analysis by Segment: 2005- 2006 (Nine Months Ended, March) (In US$ billion)
- Table 50: Annual Sales Analysis: 2004-2005 (In US$ billion)
- Table 51: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion)
- Table 52: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion)
- Table 53: Annual Sales Analysis by Quarter: 2004-2005 (In US$ billion)
- 22. Chrysalis Technologies (USA)
- 23. Cipla Limited (India)
- 24. Clement Clarke International Ltd. (UK)
- 25. Clininvent Research Pvt., Ltd. (India)
- 26. Collegium Pharmaceutical, Inc. (USA)
- 27. Cytopia Ltd. (Australia)
- Table 54: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ thousand)
- 28. Direct-Haler A/S (Denmark)
- 29. Elan Pharmaceuticals (USA)
- 30. Epigenesis Pharmaceuticals (USA)
- 31. Evogenix Ltd. (Australia)
- 32. GlaxoSmithKline PLC (UK)
- Table 55: Annual Sales Analysis: 2004-2005 (In £ million)
- Table 56: Annual Sales Analysis by Segment: 2004-2005 (In £ million)
- Glaxosmithkline Pharmaceuticals Limited (India)
- 33. Healthline Aerosol Medicine (USA)
- 34. Innovata PLC (UK)
- Table 57: Annual Sales Analysis: 2004-2005 (In £ million)
- Table 58: Annual Sales Analysis by Geographic Region: 2004-2005 (In £ million)
- 35. Inyx, Inc. (USA)
- Table 59: First Quarter Sales Analysis: 2005-2006 (In US$ million)
- Table 60: Annual Sales Analysis: 2004-2005 (In US$ million)
- 36. Isis Pharmaceuticals, Inc. (USA)
- Table 61: First Quarter Sales Analysis: 2005-2006 (In US$ million)
- Table 62: First Quarter Sales Analysis by Business Segment: 2005-2006 (In US$ million)
- Table 63: Annual Sales Analysis: 2004-2005 (In US$ million)
- Table 64: Quarterly Sales Analysis: 2004-2005 (In US$ million)
- Table 65: Annual Sales Analysis by Business Segment: 2004-2005 (In US$ million)
- 37. King Pharmaceuticals, Inc. (USA)
- Table 66: First Quarter Sales Analysis: 2005-2006 (In US$ million)
- Table 67: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ million)
- Table 68: Annual Sales Analysis: 2004-2005 (In US$ million)
- Table 69: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
- 38. Kos Pharmaceuticals, Inc. (USA)
- Table 70: First Quarter Sales Analysis: 2005-2006 (In US$ million)
- Table 71: Annual Sales Analysis: 2004-2005 (In US$ million)
- 39. Lannett Company, Inc. (USA)
- Table 72: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, March) (In US$ million)
- Table 73: Annual Sales Analysis: 2004-2005 (In US$ million)
- 40. Lincoln Pharmaceuticals Ltd. (India)
- 41. MAP Pharmaceuticals, Inc. (USA)
- 42. Markos Mefar SpA (Italy)
- 43. Merck KGAA (Germany)
- Table 74: Annual Sales Analysis: 2003-2005 (In € million)
- Table 75: Annual Sales Analysis by Segment: 2004-2005 (In € million)
- Merck Generics Group (Germany)
- 44. Nektar Therapeutics (USA)
- Table 76: Annual Sales Analysis: 2004-2005 (In US$ million)
- 45. Nic Ox SA (France)
- 46. Nigaard Pharma AS (Norway)
- 47. Novartis AG (Switzerland)
- Table 77: First Quarter Sales Analysis: 2005-2006 (In US$ million)
- Table 78: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ million)
- Table 79: Annual Sales Analysis: 2004-2005 (In US$ million)
- Table 80: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
- Table 81: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
- Sandoz Deutschland GmbH (Germany)
- 48. OM Pharma (Switzerland)
- 49. Oriel Therapeutics, Inc. (USA)
- 50. Pall Corporation (USA)
- Table 82: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, April) (In US$ million)
- Table 83: Nine Months Sales Analysis by Business Segment: 2005-2006 (Nine Months Ended, April) (In US$ million)
- Table 84: Nine Months Sales Analysis by Geographic Region: 2005-2006 (Nine Months Ended, April) (In US$ million)
- Table 85: Annual Sales Analysis: 2004-2005 (In US$ million)
- Table 86: Annual Sales Analysis by Business Segment: 2004-2005 (In US$ million)
- Table 87: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
- 51. PDL Biopharma, Inc. (USA)
- Table 88: First Quarter Sales Analysis: 2005-2006 (In US$ million)
- Table 89: Annual Sales Analysis: 2004-2005 (In US$ million)
- Table 90: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
- 52. Pfizer, Inc. (USA)
- 53. Pharmaxis Ltd. (Australia)
- 54. Profile Therapeutics (UK)
- 55. Ranbaxy Laboratories Ltd. (India)
- 56. Respirics, Inc. (USA)
- 57. Respironics, Inc. (USA)
- Table 91: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, March) (In US$ million)
- Table 92: Nine Months Sales Analysis by Quarter: 2005- 2006 (Nine Months Ended, March) (In US$ million)
- Table 93: Annual Sales Analysis: 2004-2005 (In US$ million)
- Table 94: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
- Table 95: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
- Table 96: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
- 58. Rigel Pharmaceuticals, Inc. (USA)
- Table 97: First Quarter Sales Analysis: 2005-2006 (In US$ million)
- Table 98: Annual Sales Analysis: 2004-2005 (In US$ million)
- Table 99: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
- 59. Roche Holding AG (Switzerland)
- 60. Sanofi-Aventis (France)
- Table 100: First Quarter Sales Analysis: 2005-2006 (In € million)
- Table 101: Annual Sales Analysis: 2004-2005 (In € million)
- Table 102: Annual Sales Analysis by Segment: 2004-2005 (In € million)
- Table 103: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million)
- Aventis Pharma Ltd. (India)
- 61. Schering-Plough Corporation (USA)
- Table 104: Annual Sales Analysis: 2004-2005 (In US$ million)
- Table 105: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
- Table 106: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
- Table 107: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
- 62. Sirna Therapeutics, Inc. (USA)
- Table 108: First Quarter Sales Analysis: 2005-2006 (In US$ million)
- Table 109: First Quarter Sales Analysis by Business Segment: 2005-2006 (In US$ million)
- Table 110: Annual Sales Analysis: 2004-2005 (In US$ million)
- 63. Sosei Co., Ltd. (Japan)
- Table 111: Annual Sales Analysis: 2005-2006 (In ¥ million)
- Table 112: Annual Sales Analysis: 2004-2005 (In ¥ million)
- 64. Teva Pharmaceutical Industries Ltd. (Israel)
- Teva Pharmaceuticals USA (USA)
- 65. Theravance, Inc. (USA)
- Table 113: Annual Sales Analysis: 2004-2005 (In US$ million)
- Table 114: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
- 66. Topigen Pharmaceuticals, Inc. (Canada)
- 67. UCB S.A. (Belgium)
- Table 115: Annual Sales Analysis: 2004-2005 (In € million)
- Table 116: Annual Sales Analysis by Business Segment: 2004-2005 (In € million)
- 68. Vectura Group PLC (UK)
- Table 117: Annual Sales Analysis: 2004-2005 (In £ million)
- Table 118: Annual Sales Analysis by Geographic Region: 2004-2005 (In £ million)
- 69. Zambon SpA (Italy)
More Global Allergy/Immunology Reports
The World Market for Over The Counter (OTC) Drugs by
Kalorama Information
Over-the-counter (OTC), non-legend, and non-prescription are all adjectives describing drugs that an individual may purchase without a prescription. Many pharmaceutical companies seeking more revenue and ...
Nasal Congestion Global Clinical Trials Review, H1, 2012 by
GlobalData
Nasal Congestion Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Nasal Congestion Global Clinical Trials Review, H1, 2012 provides data on the Nasal Congestion ...
Food Allergy and Intolerance Products by
Global Industry Analysts
This report analyzes the worldwide markets for Food Allergy and Intolerance Products in US$ Million by the following product segments: Gluten-free, and Others. The report ...
The 2011-2016 World Outlook for Non-Prescription Decongestants Excluding Nasal Sprays and Nose Drops by
Icon Group International, Inc.
This econometric study covers the world outlook for non-prescription decongestants excluding nasal sprays and nose drops across more than 200 countries. For each year reported, ...
Nicholas Hall's Global Cough, Cold & Allergy Review by
Nicholas Hall and Company
This essential report is the ideal guide to CCA brands and marketers across leading developed and emerging markets, focusing on core trends and exciting developments. ...
See all reports like this >>
Share this report
Other tasks Related Markets Allergy/Immunology Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
